| Literature DB >> 22817766 |
Manju Panghal1, Vivek Kaushal, Sangeeta Kadayan, Jaya Parkash Yadav.
Abstract
BACKGROUND: Over the past decade, advances in cancer treatments have been counterbalanced by a rising number of immunosuppressed patients with a multitude of new risk factors for infection. Hence, the aim of this study was to determine risk factors, infectious pathogens in blood and oral cavity of oral cancer patients undergoing different treatment procedures.Entities:
Mesh:
Year: 2012 PMID: 22817766 PMCID: PMC3499184 DOI: 10.1186/1472-6831-12-22
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Clinical and demographic data of 186 patients (62 cases per group)
| -Age in years, (median range) | 60 (25–83) |
| -Underlying disease | |
| Carcinoma of oropharynx | 12 (19.3%) |
| Carcinoma of floor of mouth | 14 (22.5%) |
| Carcinoma of base of tongue | 17 (27.4%) |
| Carcinoma of Tonsil Rt. Side | 10 (16.1%) |
| Carcinoma of last molar tooth | 9 (14.5%) |
| -Stage of cancer | |
| IInd | 14 (22.5%) |
| IIIrd | 17 (27.4%) |
| IVth | 31 (50%) |
| -Male : Female ratio | 45:17 |
| Group II | |
| -Age in years, (median range) | 45(30–65) |
| -Underlying disease | |
| Carcinoma of oropharynx | 0 |
| Carcinoma of floor of mouth | 16 (25.8%) |
| Carcinoma of base of tongue | 22 (35.4%) |
| Carcinoma of Tonsil Lt. Side | 7 (11.29%) |
| Carcinoma of Larynx | 17 (27.4%) |
| -Stage of cancer | |
| IInd | 12 (19.3%) |
| IIIrd | 25 (40.3%) |
| IVth | 25 (40.3%) |
| -Male : Female ratio | 47:15 |
| Group III | |
| -Age in years, (median range) | 50 (48–65) |
| -Underlying disease | |
| Carcinoma of oropharynx | 13 (20.9%) |
| Carcinoma of floor of mouth | 19 (30.64%) |
| Carcinoma of base of tongue | 30 (48.3%) |
| Carcinoma of Tonsil Rt. Side | 0 |
| Carcinoma of last molar tooth | 0 |
| -Stage of cancer | |
| IInd | 10 (16.1%) |
| IIIrd | 22 (35.4%) |
| IVth | 30 (48.3%) |
| -Male : Female ratio. | 50:12 |
Predisposing factors for oral cavity infection in febrile episodes of neutropenic and non- neutropenic patients in radiotherapy, chemotherapy and radio chemotherapy treated cases
| | |||
|---|---|---|---|
| Duration of neutropenia >7 | 4(6.55) 4(4.87) | 4(5.06) 4(7.01) | 4(4.34) 6(7.22) |
| | P = 0.72 | P = .71 | P = 0.52 |
| Oral mucositis (grade 0) | 3(4.91) 3(3.65) | 2(2.53) 4(7.01) | 5(5.43) 2(2.40) |
| | P = 0.70 | P = .23 | P = .44 |
| Oral mucositis (grade 1) | 4(6.55) 3(3.65) | 3(3.79) 5(8.77) | 7(7.60) 6(7.22) |
| | P = 0.45 | P = 0.27 | P = .84 |
| Oral mucositis (grade 2) | 5(8.19) 5(6.09) | 4(5.06) 5(8.77) | 9(9.78) 4(4.81) |
| | P = .74 | P = 0.49 | P = .33 |
| Oral mucositis (grade 3) | 8(13.11) 8(9.75) | 19(24.05) 5(8.77) | 11(11.95) 7(8.43) |
| | P = 0.71 | P = 0.05* | P = .60 |
| Oral mucositis (grade 4) | 9(14.75) 25(30.48) | 11(13.92) 13(22.80) | 32(34.78) 12(14.45) |
| | P < .05* | P =0.26 | P < .001*** |
| Anemia | 4(6.55) 3(3.65) | 5(6.32) 3(5.26) | 5(5.43) 4(4.81) |
| | P = .45 | P = 1 | P = 1 |
| Central venous line present | 6(9.83) 7(8.53) | 9(11.39) 7(12.28) | 7(7.60) 15(18.07) |
| | P = .97 | P = .91 | P = .06 |
| Peripheral line present | 5(8.19) 3(3.65) | 7(8.86) 5(8.77) | 4(4.34) 9(10.84) |
| | P = .28 | P = 77 | P = .17 |
| Community acquired | 6(9.83) 17(20.73) | 6(7.59) 3(5.26) | 3(3.26) 9(10.84) |
| | P = 0.12 | P = .73 | P = .09 |
| Nosocomial acquired | 7(11.47) 4(4.87) | 9(11.39) 3(5.26) | 5(5.43) 9(10.84) |
| P = .20 | P = .34 | P = 0.29 |
Note: % had been shown in parenthesis, the value in table shows number of patients, ANC = absolute neutrophil count, ANC of < 500 neutrophil/micro L (neutropenic), ANC ≥ 500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC > 500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly Significant.
Predominant pathogens isolated from oral cavity of neutropenic and non-neutropenic patients treated with radiotherapy, chemotherapy and radiochemotherapy (Group I, II, III)
| (A)Gram + ive | 13(21.3) | 12(14.6) | 1.58(0.61-4.0) | 0.41 | 25(31.6) | 18(31.5) | 1.00(0.45-2.2) | 0.85 | 39(42.3) | 31(37.3) | 1.23(0.6-2.3) | 0.59 |
| 8(13.1) | 6(7.3) | 1.60(0.25-10.7) | 0.85 | 18(22.7) | 11(19.2) | 1.64(0.38-7.2) | 0.67 | 29(31.5) | 15(18) | 3.09(1.0-9.6) | <0.05* | |
| 5(8.1) | 6(7.3) | 0.63(0.09-4.0) | 0.85 | 7(8.8) | 7(12.28) | 0.61(0.14-2.2) | 0.67 | 10(10.8) | 16(19.2) | 0.32(0.1-0.9) | <0.05* | |
| (B)Gram -ive | 20(32.9) | 18(21.9) | 1.25(0.57-2.7) | 0.68 | 43(54.4) | 33(57.8) | 0.87(0.41-1.8) | 0.82 | 22(23.9) | 29(34.9) | 0.59(0.2-1.1) | 0.15 |
| 4(6.5) | 6(7.3) | 0.50(0.09-2.6) | 0.46 | 7(8.8) | 8(14.3) | 0.61(0.17-2.1) | 0.56 | 6(6.5) | 8(9.6) | 0.98(0.2-4.0) | .77 | |
| 3(4.9) | 4(4.8) | 0.62(0.09-4.1) | 0.68 | 5(6.3) | 4(7) | 0.95(0.20-4.7) | 1.00 | 5(5.4) | 7(8.4) | 0.92(0.2-4.0) | 0.82 | |
| 5(8.1) | 5(6.0) | 0.87(0.16-4.5) | 1 | 27(34.1) | 13(22.8) | 2.60(0.93-7.3) | < 0.05* | 4(4.3) | 5(6) | 1.07(0.2-5.5) | 1 | |
| 5(8.1) | 3(3.6) | 3(0.41-26.4) | 0.40 | 4(5.0) | 6(10.5) | 0.46(0.10-2.1) | 0.31 | 4(4.3) | 5(6) | 1.07(0.2-5.5) | 1 | |
| 3(3.8) | 0 | UN | 0.23 | 0 | 2(3.5) | 0.00(0.00-3.14)6 | 0.18 | 3(3.2) | 4(4.8) | 0.99(0.1-6.1) | 1 | |
| (C) Fungi | 28(45.9) | 52(63.4) | 0.49(0.24-1.0) | < 0.05* | 11(13.9) | 6(10.5) | 1.38(0.43-4.5) | 0.74 | 31(33.6) | 23(27.7) | 1.33(0.6-2.6) | 0.48 |
| 28(45.9) | 40(48.7) | 1.30 (1.12-1.5) | < . 001***0 | 7(8.8) | 6(10.5) | 0.00(0.00-2.8) | 0.23 | 26(28.2) | 23(27.7) | 0.00(0.0-1.5) | <.05* | |
| 0 | 12 | UN | .02 | 4(5.0) | 0 | UN | 1.0 | 5(5.4) | 0 | UN | 1 | |
Note: n = number of pathogens, UN: Undefined, % had been shown in parenthesis, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC >500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC >500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly significant.
Predisposing factors for bloodstream infection in febrile episodes of neutropenic and non- neutropenic patients in radiotherapy, chemotherapy and radio chemotherapy treated cases
| Duration of neutropenia >7 | 5(7.81) 4(4.70) | 6(6.6) 4(7.27) | 10(8.92) 6(6.31) |
| | P = 0.49 | P = 1 | P = 0.65 |
| Oral mucositis (grade 0) | 5(7.81) 3(3.52) | 5(5.55) 4(7.27) | 5(4.46) 2(1.78) |
| | P = 0.28 | P = .73 | P = .45 |
| Oral mucositis (grade 1) | 6(9.37) 3(3.52) | 2(2.22) 5(9.09) | 7(6.25) 6(6.31) |
| P = 0.17 | P = 0.10 | P = .78 | |
| Oral mucositis (grade 2) | 4(6.25) 5(5.88) | 4(4.44) 5(9.09) | 12(10.71) 4 (4.21) |
| P = 1 | P = 0.30 | P = .13 | |
| Oral mucositis (grade 3) | 5(7.81) 8(9.41) | 9(10) 6(10.90) | 15(13.39) 7(7.36) |
| P = 0.78 | P = 0.91 | P = .23 | |
| Oral mucositis (grade 4) | 7(10.93) 25(29.41) | 11(12.22) 12(21.81) | 32(28.57) 12(12.63) |
| P < .01** | P =0.19 | P < .001*** | |
| Anemia | 4(6.25) 3(3.52) | 10(11.11) 3(5.45) | 9(8.03) 6(6.31) |
| P = .46 | P = .37 | P = .83 | |
| Central venous line present | 8(12.5) 7(8.23) | 15(16.6) 5(9.09) | 7(6.25) 15(15.78) |
| P = .56 | P = .30 | P = .05* | |
| Peripheral line present | 5(7.81) 3(3.52) | 9(10) 5(9.09) | 4(3.57) 10(10.52) |
| P = .02 | P = 91 | P = .08 | |
| Community acquired | 6(9.37) 20(23.52) | 6(6.06) 2(3.63) | 6(5.35) 11(11.57) |
| P < .05* | P = .71 | P = .17 | |
| Nosocomial acquired | 9(14.06) 4(4.70) | 13(14.44) 4(7.27) | 5(4.46) 16(16.84) |
| P = .08 | P = .29 | P < .001*** |
Note: % had been shown in parenthesis, the value in table shows number of patients, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC ≥500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC >500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly Significant.
Predominant pathogens isolated from blood of neutropenic and non-neutropenic patients treated with radiotherapy, chemotherapy and radio-chemotherapy (Group I, II. III)
| (A)Gram + ive | 23(35.9) | 18(21.1) | 2.09(0.95-4.6) | 0.07 | 52(5.7) | 25(45.4 | 1.64(0.7-3.4) | 0.20 | 61( 54.4) | 35(36.8) | 2.0(1.1-3.7) | < 0.01** |
| 15(23.4) | 12(14.1) | 0.94(0.21-4.1) | 0.81 | 42(4.6) | 11(2) | 5.35 (1.6-17.6) | < .001** | 21( 18.7) | 28(29.4) | 0.1(0.0-0.3) | < .001*** | |
| 8(12.5) | 6(7.0) | 1.07(0.24-4.7) | 0.81 | 10(1.1) | 14(25.4) | 0.19(0.0-0.6) | < .001** | 40(35.7) | 7(7.3) | 7.6(2.6-23.1) | < .001*** | |
| (B)Gram -ive | 26(40.6) | 56(65.8) | 0.35(0.1-0.7) | < 0.001*** | 24(2.6) | 22(4) | 0.55(0.2-1.1) | 0.13 | 39(34.8) | 42(44.2) | 0.67(0.3-1.2) | 0.21 |
| 10(15.6) | 9(10.5) | 0.34(0.1-0.9) | 0.04 | 7(7.7) | 6(10.9) | 1.10(0.2-4.7) | 0.85 | 11(9.8) | 17(17.8) | 0.58(0.2-1.6) | 0.35 | |
| 6(9.3) | 28(32.9) | 0.30(0.0-0.9) | < 0.05* | 7(7.7) | 7(12.7) | 0.88(0.2-3.7) | 0.90 | 12(10.7) | 12(12.6) | 1.11(0.3-3.2) | 0.97 | |
| 5(7.8) | 14(16.4) | 0.71(0.1-2.5) | 0.76 | 6(6.6) | 5(9.0) | 1.13(0.2-5.4) | 0.86 | 10(8.9) | 7(7.3) | 1.72(0.5-5.8) | 0.47 | |
| 5(7.8) | 5(5.8) | 2.43(0.5-11.1) | 0.27 | 4(4.4) | 3(5.4) | 1.27(0.2-8.4) | 1.00 | 4(3.5) | 5(5.2) | 0.85(0.1-4.0) | 1 | |
| 0 | 0 | 0 | 0 | 0 | 1(1.8) | 0.00(0.0-16.4) | 0.47 | 2(1.7) | 1(1.0) | 1.84(0.1-53.7) | 1 | |
| (C) Fungi | 15(23.4) | 11(12.9) | 2.06(0.8-5.2) | 0.14 | 14(15. 5) | 8(14.5) | 1.20(0.4-3.3) | 0.88 | 12(10.7) | 18(18.9) | 0.51(0.2-1.2) | 0.13 |
| 9(14.0) | 6(7.0) | 1.25(0.2-8.0) | 1.00 | 8(8.8) | 5(9.0) | 0.80(0.0-6.5) | 1.00 | 7(6.2) | 10(10.5) | 1.12(0.2-6.3) | 0.82 | |
| 6(9.3) | 5(5.8) | 0.80(0.1-5.0) | 1.00 | 6(6.6) | 3(5.4) | 1.25(0.1-10.5) | 1.00 | 5(4.4) | 8(8.4) | 0. 89(0.1-4.9) | 0.82 | |
Note: n = number of pathogens, % had been shown in parenthesis, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC > 500 neutrophil/micro L (non-neutropenic). P = Probability value of patients with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC >500 neutrophil/micro L (non-neutropenic). P < .05 * less significant, P < .01 ** significant, P < .001 *** highly significant.